Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA Moves to Reevaluate Several Peptides American Med Spa Association The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Warning Letter Breakdown: Testing the Line Between Consumer Wellness Claims and Regulated Physiologic Measurement Functions in Wearables